Mitapivat metabolically reprograms human β-thalassemic erythroblasts, increasing their responsiveness to oxidation
Abstract: β-thalassemia (β-thal) is a worldwide hereditary red cell disorder characterized by severe chronic anemia. Recently, the pyruvate kinase (PK) activator mitapivat has been shown to improve anemia and ineffective erythropoiesis in a mouse model of β-thal and in patients with non–transfusion-...
Saved in:
| Main Authors: | Angela Siciliano, Angelo D’Alessandro, Alessandro Matte, Giovanni Bisello, Mariarita Bertoldi, Monika Dzieciatkowska, Amy Argabright, Richard Huot Pozzetto, Veronica Riccardi, Andrea Mattarei, Alberto Ongaro, Jacopo Ceolan, Roberta Russo, Leonardo Rivadeneyra, Megan Wind-Rotolo, Achille Iolascon, Carlo Brugnara, Lucia De Franceschi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erythroblast Enucleation
by: Ganesan Keerthivasan, et al.
Published: (2011-01-01) -
Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
by: Khaled M. Musallam, et al.
Published: (2025-07-01) -
Erythroblast island macrophages and their surface markers
by: Mei Fang, et al.
Published: (2025-05-01) -
Coagulation defects in thalassemic patients
by: Mostafa M. Abosdera, et al.
Published: (2017-10-01) -
Scalable in vitro production of defined mouse erythroblasts.
by: Helena S Francis, et al.
Published: (2022-01-01)